NO3037424T3 - - Google Patents

Info

Publication number
NO3037424T3
NO3037424T3 NO14837210A NO14837210A NO3037424T3 NO 3037424 T3 NO3037424 T3 NO 3037424T3 NO 14837210 A NO14837210 A NO 14837210A NO 14837210 A NO14837210 A NO 14837210A NO 3037424 T3 NO3037424 T3 NO 3037424T3
Authority
NO
Norway
Application number
NO14837210A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO3037424T3 publication Critical patent/NO3037424T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
NO14837210A 2013-08-22 2014-08-22 NO3037424T3 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013172746 2013-08-22
PCT/JP2014/071951 WO2015025936A1 (ja) 2013-08-22 2014-08-22 新規キノリン置換化合物

Publications (1)

Publication Number Publication Date
NO3037424T3 true NO3037424T3 (cg-RX-API-DMAC7.html) 2018-04-07

Family

ID=52483707

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14837210A NO3037424T3 (cg-RX-API-DMAC7.html) 2013-08-22 2014-08-22

Country Status (21)

Country Link
US (2) US9650386B2 (cg-RX-API-DMAC7.html)
EP (1) EP3037424B1 (cg-RX-API-DMAC7.html)
JP (1) JP6161705B2 (cg-RX-API-DMAC7.html)
KR (1) KR101906688B1 (cg-RX-API-DMAC7.html)
CN (1) CN105683195B (cg-RX-API-DMAC7.html)
AU (1) AU2014309788B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016003247B1 (cg-RX-API-DMAC7.html)
CA (1) CA2922077C (cg-RX-API-DMAC7.html)
DK (1) DK3037424T3 (cg-RX-API-DMAC7.html)
ES (1) ES2656712T3 (cg-RX-API-DMAC7.html)
HU (1) HUE034807T2 (cg-RX-API-DMAC7.html)
MX (1) MX370808B (cg-RX-API-DMAC7.html)
MY (1) MY182891A (cg-RX-API-DMAC7.html)
NO (1) NO3037424T3 (cg-RX-API-DMAC7.html)
PH (1) PH12016500225B1 (cg-RX-API-DMAC7.html)
PL (1) PL3037424T3 (cg-RX-API-DMAC7.html)
PT (1) PT3037424T (cg-RX-API-DMAC7.html)
RU (1) RU2689158C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201600759XA (cg-RX-API-DMAC7.html)
TW (1) TWI603971B (cg-RX-API-DMAC7.html)
WO (1) WO2015025936A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI603971B (zh) * 2013-08-22 2017-11-01 Taiho Pharmaceutical Co Ltd Novel quinoline substituted compounds
AU2017350440B2 (en) * 2016-10-31 2023-01-12 Taiho Pharmaceutical Co., Ltd. Selective inhibitor of exon 20 insertion mutant EGFR
BR112019010020A2 (pt) * 2016-11-17 2019-08-20 Univ Texas compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
FR3068971B1 (fr) * 2017-07-12 2019-08-30 Protneteomix Acides 5-{4-allyl-5-[2-(4-alcoxyphenyl)quinolein-4-yl]-4h-1,2,4-triazole-3-ylsulphanylmethyl}furan-2-carboxyliques dans le traitement du cancer
FI3677266T3 (fi) * 2017-09-01 2024-03-22 Taiho Pharmaceutical Co Ltd Eksoni 18- ja/tai eksoni 21 -egfr-mutantille selektiivinen inhibiittori
CN113423403B (zh) * 2018-12-28 2025-02-18 大鹏药品工业株式会社 对l718和/或l792突变型治疗有抗性的egfr抑制剂
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
JP7109013B2 (ja) 2019-03-19 2022-07-29 ボロノイ インコーポレイテッド ヘテロアリール誘導体、ヘテロアリール誘導体の生成方法、およびヘテロアリール誘導体を有効成分として含む医薬組成物
US12629375B2 (en) 2019-03-29 2026-05-19 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing HER2 exon 21 insertions
WO2021057796A1 (zh) * 2019-09-29 2021-04-01 深圳市塔吉瑞生物医药有限公司 取代的稠合三环衍生物及其组合物及用途
WO2021127456A1 (en) 2019-12-19 2021-06-24 Rain Therapeutics Inc. Methods of inhibiting epidermal growth factor receptor proteins
CN113861195B (zh) * 2020-06-30 2022-11-18 上海和誉生物医药科技有限公司 一种多稠环egfr抑制剂及其制备方法和应用
CN116096372B (zh) * 2020-07-09 2024-09-03 上海和誉生物医药科技有限公司 一种egfr抑制剂、其制备方法和在药学上的应用
US20230372346A1 (en) * 2020-09-08 2023-11-23 Cullinan Pearl Corp. Treatment regimens for exon-20 insertion mutant egfr cancers
WO2022121967A1 (zh) * 2020-12-09 2022-06-16 南京药石科技股份有限公司 Egfr酪氨酸激酶抑制剂及其用途
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
JP2024523861A (ja) * 2021-06-15 2024-07-02 ジェネンテック, インコーポレイテッド がんを処置するための併用療法におけるegfr阻害剤およびperk活性化剤、ならびにこれらの使用
CN115707704B (zh) * 2021-08-20 2024-09-13 广东医诺维申生物技术有限公司 氘代稠合三环类化合物及其组合物和用途
CN120641417A (zh) * 2022-12-08 2025-09-12 亚细亚化学工业有限公司 齐帕勒替尼的固态形式及其制备方法
CN115785107B (zh) * 2022-12-15 2024-11-12 南京雷正医药科技有限公司 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途
EP4722218A1 (en) * 2023-05-31 2026-04-08 Taiho Pharmaceutical Co., Ltd. Crystal of quinoline-substituted compound
CN122206681A (zh) 2023-12-27 2026-06-12 阿西亚化学工业有限公司 Zipalertinib盐酸盐的固态形式及其制备工艺
WO2025167588A1 (zh) * 2024-02-05 2025-08-14 苏州科睿思制药有限公司 Zipalertinib的晶型及其制备方法和用途
WO2026095022A1 (ja) * 2024-11-01 2026-05-07 大鵬薬品工業株式会社 キノリン置換化合物の結晶

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW440562B (en) 1994-05-20 2001-06-16 Taiho Pharmaceutical Co Ltd Condensed-indan derivative and pharmaceutically acceptable salts thereof
WO2006102079A1 (en) 2005-03-17 2006-09-28 Novartis Ag N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase
SG177306A1 (en) 2009-07-10 2012-02-28 Taiho Pharmaceutical Co Ltd Azabicyclo compound and salt thereof
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
CA2824013A1 (en) 2011-01-07 2012-07-12 Taiho Pharmaceutical Co., Ltd. Novel bicyclic compound or salt thereof
WO2013047813A1 (ja) * 2011-09-30 2013-04-04 大鵬薬品工業株式会社 1,2,4-トリアジン-6-カルボキサミド誘導体
TWI594986B (zh) 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
TW201336847A (zh) 2012-02-07 2013-09-16 Taiho Pharmaceutical Co Ltd 喹啉基吡咯并嘧啶化合物或其鹽
US8889666B2 (en) 2012-02-23 2014-11-18 Taiho Pharmaceutical Co., Ltd. Quinolyl pyrrolo pyrimidyl condensed-ring compound and salt thereof
KR20150119401A (ko) * 2013-02-22 2015-10-23 다이호야쿠힌고교 가부시키가이샤 3환성 화합물의 제조 방법 및 상기 제조 방법에 의해 얻을 수 있는 3환성 화합물
TWI603971B (zh) * 2013-08-22 2017-11-01 Taiho Pharmaceutical Co Ltd Novel quinoline substituted compounds

Also Published As

Publication number Publication date
JP6161705B2 (ja) 2017-07-12
SG11201600759XA (en) 2016-03-30
US20170101414A1 (en) 2017-04-13
HK1222393A1 (zh) 2017-06-30
RU2019114688A (ru) 2020-07-29
PH12016500225A1 (en) 2016-05-02
PT3037424T (pt) 2017-12-18
US9650386B2 (en) 2017-05-16
KR20160043114A (ko) 2016-04-20
BR112016003247B1 (pt) 2022-05-10
MX370808B (es) 2020-01-07
EP3037424B1 (en) 2017-11-08
ES2656712T3 (es) 2018-02-28
HUE034807T2 (en) 2018-02-28
MY182891A (en) 2021-02-05
CA2922077A1 (en) 2015-02-26
MX2016002125A (es) 2016-06-28
US20160194332A1 (en) 2016-07-07
AU2014309788B2 (en) 2017-02-16
RU2016110096A (ru) 2017-09-27
BR112016003247A2 (cg-RX-API-DMAC7.html) 2017-08-01
EP3037424A1 (en) 2016-06-29
RU2689158C2 (ru) 2019-05-24
KR101906688B1 (ko) 2018-10-10
AU2014309788A1 (en) 2016-03-10
CN105683195A (zh) 2016-06-15
TWI603971B (zh) 2017-11-01
TW201542547A (zh) 2015-11-16
PL3037424T3 (pl) 2018-03-30
CN105683195B (zh) 2017-11-10
DK3037424T3 (en) 2017-12-11
PH12016500225B1 (en) 2016-05-02
EP3037424A4 (en) 2017-01-25
JPWO2015025936A1 (ja) 2017-03-02
WO2015025936A1 (ja) 2015-02-26
RU2016110096A3 (cg-RX-API-DMAC7.html) 2018-06-18
CA2922077C (en) 2018-06-26
US9758526B2 (en) 2017-09-12

Similar Documents

Publication Publication Date Title
AP2016009275A0 (cg-RX-API-DMAC7.html)
BR112016014083A2 (cg-RX-API-DMAC7.html)
BR112016011851A2 (cg-RX-API-DMAC7.html)
BR112015007533A2 (cg-RX-API-DMAC7.html)
BR112016010832A2 (cg-RX-API-DMAC7.html)
BR102016010778A2 (cg-RX-API-DMAC7.html)
BR112014017733A2 (cg-RX-API-DMAC7.html)
BR112014017739A2 (cg-RX-API-DMAC7.html)
BR112014018502A2 (cg-RX-API-DMAC7.html)
BR112014018516A2 (cg-RX-API-DMAC7.html)
BR112014017765A2 (cg-RX-API-DMAC7.html)
BR112014018480A2 (cg-RX-API-DMAC7.html)
BR112014017855A2 (cg-RX-API-DMAC7.html)
BR112014020341A2 (cg-RX-API-DMAC7.html)
RU2016110096A3 (cg-RX-API-DMAC7.html)
BR112016005150A2 (cg-RX-API-DMAC7.html)
BR112016013169A2 (cg-RX-API-DMAC7.html)
BR112015030872A2 (cg-RX-API-DMAC7.html)
BR112014017901A2 (cg-RX-API-DMAC7.html)
BR112014017722A2 (cg-RX-API-DMAC7.html)
BR112015023202A2 (cg-RX-API-DMAC7.html)
BR112014018578A2 (cg-RX-API-DMAC7.html)
BR112014017601A2 (cg-RX-API-DMAC7.html)
BR112015015312A2 (cg-RX-API-DMAC7.html)
BR112014024039A2 (cg-RX-API-DMAC7.html)